Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
This activity is supported by an educational grant from Juno Therapeutics.
December 8, 2017
Lunch and registration: 12:30 PM – 1:30 PM
Georgia World Congress Center
Meeting Room: B308-B309
285 Andrew Young International Blvd NW
Atlanta, GA 30313
Registration is complimentary, but seating is limited.
Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh In on Recent Data and Clinical Experience is a live symposium to be held adjunct to the annual meeting in Atlanta. Outcomes for patients with lymphoid malignancies have improved dramatically over the past several decades as a result of personalization of care and the use of targeted agents in multiple lines of therapy. However, important unmet clinical needs remain, particularly for patients with relapsed/refractory disease.
Chimeric antigen receptor (CAR) T cells have recently emerged as a novel therapeutic approach, yielding complete responses even in heavily pretreated patients with leukemia, lymphoma, and myeloma; they also are being explored in solid tumors. However, CAR T cells represent a major paradigm shift from conventional management strategies, and there is a clear educational need to address knowledge and competence gaps among physicians regarding clinical data with CAR T cells, key considerations in the administration of these agents, and methods to manage the unique spectrum of treatment-related adverse events associated with these therapies.
To address these educational gaps, this symposium will feature internationally renowned experts in CAR T-cell therapy who will discuss the science and clinical data underlying these new therapeutic approaches, as well as practical advice for incorporating CAR T cells in treatment algorithms for patients with lymphoid malignancies. Extended question-and-answer sessions will also provide opportunities for interaction between the expert faculty and participants.
Key topics to be addressed by faculty include:
The symposium will be held at the Georgia World Congress Center, on December 8, 2017, from 12:30 PM to 4:30 PM. Please join us in Atlanta to learn about the latest developments in CAR T-cell therapy in hematologic malignancies. This is a symposium not to be missed!
These activities are intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the use of CAR T-cell therapy for patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of patients with hematologic malignancies are also invited to attend.
Upon completion of this activity, participants will be able to:
David Maloney, MD, PhD
Member, Clinical Research Division
Fred Hutchinson Cancer Research Center
Professor of Medicine, Division of Oncology
University of Washington
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018